Sangamo Announces ASGCT 2024

Sangamo Announces Transition of SAR445136 Sickle Cell Disease Program From Sanofi to Sangamo

The Companies are collaborating on an orderly transition through first half of 2022 while Sangamo explores options to advance the program, including seeking a new partner Phase 1/2 PRECIZN-1 study of investigational SAR445136 expected to be completed as planned; final patients in study expected to